Counterpoint Mutual Funds LLC Takes $4.26 Million Position in Adaptive Biotechnologies Corporation $ADPT

Counterpoint Mutual Funds LLC purchased a new position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 307,268 shares of the company’s stock, valued at approximately $4,265,000.

A number of other large investors have also modified their holdings of the company. Westfield Capital Management Co. LP acquired a new stake in shares of Adaptive Biotechnologies in the fourth quarter valued at approximately $65,942,000. Price T Rowe Associates Inc. MD boosted its position in shares of Adaptive Biotechnologies by 303.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after buying an additional 3,299,635 shares during the period. Ameriprise Financial Inc. grew its holdings in Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after buying an additional 2,731,648 shares in the last quarter. Invesco Ltd. grew its holdings in Adaptive Biotechnologies by 248.8% in the 4th quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock worth $50,468,000 after buying an additional 2,216,595 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its position in Adaptive Biotechnologies by 544.0% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after acquiring an additional 2,062,282 shares during the period. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies Price Performance

Shares of NASDAQ:ADPT opened at $21.19 on Friday. The stock has a market cap of $3.39 billion, a price-to-earnings ratio of -64.21 and a beta of 2.07. Adaptive Biotechnologies Corporation has a 12 month low of $9.96 and a 12 month high of $22.80. The stock’s 50 day moving average price is $16.09 and its 200 day moving average price is $15.86.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The firm had revenue of $70.87 million during the quarter, compared to analyst estimates of $61.03 million. During the same period last year, the company posted ($0.20) EPS. The firm’s quarterly revenue was up 35.1% on a year-over-year basis. On average, sell-side analysts expect that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Kyle Piskel sold 3,115 shares of Adaptive Biotechnologies stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $13.04, for a total transaction of $40,619.60. Following the transaction, the chief financial officer directly owned 256,725 shares of the company’s stock, valued at $3,347,694. The trade was a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Harlan S. Robins sold 6,160 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $18.01, for a total transaction of $110,941.60. Following the completion of the sale, the insider owned 1,405,898 shares in the company, valued at approximately $25,320,222.98. This trade represents a 0.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 698,316 shares of company stock valued at $11,655,488. 5.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ADPT shares. Morgan Stanley reduced their price target on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. BTIG Research reissued a “buy” rating and set a $22.00 price target on shares of Adaptive Biotechnologies in a report on Wednesday, June 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. TD Cowen upped their price objective on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.50.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.